Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study by Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone

Get full text